8-KEarnings & ResultsExhibits & Filings

ALNYLAM PHARMACEUTICALS, INC. 8-K Report, Financial Results (May 6, 2020)

Filed May 6, 2020For Securities:ALNY

Summary

Alnylam Pharmaceuticals, Inc. (ALNY) reported its first quarter 2020 financial results on May 6, 2020. While the 8-K filing itself primarily serves to announce the earnings release, the underlying press release (Exhibit 99.1) would contain the detailed financial performance and operational updates for the quarter ending March 31, 2020. Investors should focus on revenue generation from key products, progress in clinical development pipelines, and any strategic updates or guidance provided by management. As this filing is furnished and not formally 'filed' under Section 18 of the Exchange Act, it's important to note that the information's legal standing differs. However, the press release within is the primary source for understanding the company's performance and outlook. Key areas of interest would typically include sales figures for marketed products like ONPattro and GIVLAARI, updates on the commercial launch of OXLUMO, and the status of its pipeline programs, particularly those targeting rare genetic diseases and cardio-metabolic diseases.

Key Highlights

  • 1Announcement of Q1 2020 financial results on May 6, 2020.
  • 2The press release containing the detailed financial results is furnished as Exhibit 99.1.
  • 3The filing includes standard Cover Page Interactive Data File as Exhibit 104.
  • 4Information furnished under Item 2.02 is not considered 'filed' for Section 18 purposes, but serves as the official release of earnings data.
  • 5Investors should refer to the furnished press release for specific financial metrics and operational updates.

Frequently Asked Questions

The main purpose of this 8-K filing is to officially announce Alnylam Pharmaceuticals, Inc.'s financial results for the quarter ended March 31, 2020, by furnishing the accompanying press release.

The detailed financial results and operational updates are contained within the press release furnished as Exhibit 99.1 to this 8-K filing.

While this 8-K filing's primary purpose is to report financial results, the furnished press release (Exhibit 99.1) typically includes management's commentary, strategic updates, and forward-looking guidance which investors should review for this information.

Information 'furnished' under Item 2.02 is made public by the company but does not carry the same legal liability under Section 18 of the Exchange Act as information formally 'filed'. However, for investors, it serves as the official release of the earnings information.